In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4478-4482

  Saravolatz, Louis D ^a,b   Pawlak, Joan ^a   Johnson, Leonard ^a,b   Bonilla, Hector ^c   Saravolatz II, Louis D ^a   Fakih, Mohamad G ^a,b   Fugelli, Anders ^d   Olsen, Wenche Marie ^d  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d LYTIX BIOPHARMA AS   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; LTX 109; MINOCYCLINE; POLYPEPTIDE ANTIBIOTIC AGENT; PSEUDOMONIC ACID; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; METHICILLIN; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OLIGOPEPTIDES; OXAZOLIDINONES; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84864381356     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00194-12     Document Type: Article

References (16)

1. Babu T, Rekasius V, Parada JP, Schreckenberger P, Challapalli M. 2009. Mupirocin resistance among methicillin-resistant Staphylococcus aureus-colonized patients admission to a tertiary care medical center. J. Clin. Microbiol. 47:2279-2280.
2. Clinical and Laboratory Standards Institute. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guidelines. M26-A. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing, 18th informational supplement M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Goossens H, Ferech M, Vander Stichele R, Elseviers M. 2005. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 365:579-587. (Pubitemid 40247914)
5. Haug BE, Stensen W, Kalaaji M, Rekdal O, Svendsen JS. 2008. Synthetic antimicrobial peptidomimetics with therapeutic potential. J. Med. Chem. 51:4306-4314. (Pubitemid 352032455)
6. Isaksson J, et al. 2011. A synthetic antimicrobial peptidomimetic (LTX-109): stereochemical impact on membrane disruption. J. Med. Chem. 54:5786-5795.
7. Isenberg HD, (ed). 2004. Clinical microbiology procedures handbook, p 5.10.2.1. ASM Press, Washington, DC.
8. Morrissey I, Fugelli A, Stensen W, Svendsen JS. 2009. Studies on resistance development to LTX-109, a novel antimicrobial peptide, abstr. P1082. Abstr. 19th Eur. Congr. Clin. Microbiol. Infect. Dis.
9. Mortensen B, Fugelli A, Olsen WM. 2011. Evaluation of the preclinical safety and tolerability profile of LTX-109 a novel antimicrobial drug, abstr A2-031. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother.
10. Olsen WM, et al. 2011. LTX-109 is active against CA-MRSA (USA300) and S. pyogenes in a mouse skin infection model, abstr A2-030. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother.
11. Olsen WM, et al. 2011. LTX-109 is an effective, novel agent for nasal decolonization of MRSA/MSSA-results from a phase I/IIa study, abstr. L1-275. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother.
12. Pakyz AL, MacDougall C, Oinonen M, Polk RE. 2008. Trends in anti-bacterial use in US academic health centers: 2002 to 2006. Arch. Intern. Med. 168:2254-2260.
13. Pearson D, Steigbigel RT, Davis HT, Chapman SW. 1980. Methods for reliable determination of minimal lethal antibiotic concentrations. Antimicrob. Agents Chemother. 18:699-708. (Pubitemid 11164141)
14. Ryge TS, Frimodt-Möller N, Hansen PR. 2008. Antimicrobial activities of twenty lysine-peptoid hybrids against clinically relevant bacteria and fungi. Chemotherapy 54:152-156. (Pubitemid 351448603)
15. Saravolatz L, Pawlak J, Johnson L. 2010. In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycinintermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 54:3027-3030.
16. Swenson JM, et al. 2010. Multicenter study to determine disk diffusion and broth microdilution criteria for prediction of high- and low-level mupirocin resistance in Staphyloccus aureus. J. Clin. Microbiol. 48:2469-2475.